『Glioblastoma aka GBM』のカバーアート

Glioblastoma aka GBM

Glioblastoma aka GBM

著者: Amber Barbach
無料で聴く

このコンテンツについて

Glioblastoma aka GBM is a podcast by the Glioblastoma Research Organization that highlights the stories of our community, from Glioblastoma Warriors, to caregivers, medical advisors, and more. Glioblastoma aka GBM is hosted by Amber Barbach, who founded the Glioblastoma Research Organization in 2018, after her father was diagnosed with and passed away from Glioblastoma. This podcast is an exploration of stories and personal experiences, and is not meant to be taken as medical advice of any kind. If you have questions, always consult with your own medical providers and healthcare team. You are warmly invited to connect with the team at the Glioblastoma Research Organization, and share your own stories and experiences. For more information, please visit gbmresearch.org.2022 社会科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Soundwaves and Surgery: Carthera’s Work in Brain Tumor Therapy
    2025/09/27
    In this episode, we explore Carthera, a French biotech company developing novel ultrasound-based technologies to improve drug delivery to the brain. Based in Paris and spun out from academic research, Carthera is best known for its implantable device, SonoCloud, which uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier. This allows for increased drug penetration into brain tumors, addressing one of the major challenges in treating diseases like glioblastoma. This episode features leadership and key collaborators from Carthera, including CEO Frédéric Sottilini, who shares how his background in therapeutic ultrasound and medical device development helped guide the company’s path from concept to clinical trials. We are also joined by Professor Alexandre Carpentier, MD, PhD, the neurosurgeon who founded Carthera, and Michael Vogelbaum, MD, PhD, Chief of Neurosurgery at Moffitt Cancer Center, who offers his perspective as a clinical investigator working with the company’s technology. This episode offers insight into the intersection of engineering, neurosurgery, and translational research, and the collaborative effort required to develop new treatment tools for brain tumor patients. Learn more at https://carthera.eu/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.
    続きを読む 一部表示
    53 分
  • GLIOMATCH: Advancing Glioblastoma Research at KU Leuven
    2025/07/17
    In this episode, we visit KU Leuven in Belgium to explore GLIOMATCH, a groundbreaking European research initiative working to improve outcomes for adults and children with glioblastoma through collaboration across neurosurgery, oncology, immunology, and spatial omics. We speak with the experts leading this innovative work. Frederik De Smet, Professor and GLIOMATCH Project Coordinator at KU Leuven, outlines the vision for the project and how it brings together multiple disciplines to tackle one of the most challenging forms of cancer. Steven De Vleeschouwer, MD, PhD, Neurosurgeon and expert in immunotherapy trials, shares how surgical intervention plays a key role not only in treatment but also in advancing research. Paul M. Clement, MD, Medical Oncologist specializing in adult neuro-oncology, discusses the complexities of post-surgical care and how GLIOMATCH is helping improve decision-making. Sandra Jacobs, MD, Pediatric Neuro-Oncologist, highlights the unique challenges in treating children and the need for tailored research approaches. Thierry Voet, PhD, Chair of the Leuven Institute for Single-Cell Omics, explains how cutting-edge spatial omics is transforming our understanding of glioblastoma biology. Abhishek D. Garg, PhD, Tumor Immunology Specialist, shares how data science and deep immune profiling are driving new insights into overcoming immunotherapy resistance. GLIOMATCH is a testament to the power of collaboration in pushing the boundaries of glioblastoma research and offering hope for patients and families worldwide. This work is funded by the European Union. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them. This work is also supported by Innovate UK [grant number 10113516] and the Swiss State Secretariat for Education, Research and Innovation (SERI) under the contract number 23.00607. Learn more at www.gliomatch.eu This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.
    続きを読む 一部表示
    1 時間 1 分
  • Unlocking Pediatric Brain Tumors at Bambino Gesù
    2025/07/03
    In this episode, we visit Bambino Gesù Children’s Hospital in Rome to explore the pioneering pediatric brain tumor research being led by Maria Vinci, MD. Her team focuses on high-grade pediatric brain tumors including diffuse midline gliomas, with the goal of advancing more personalized and effective therapies for children around the world. We tour three key research labs that play a central role in their work: the patient-derived model lab, the high-content imaging lab, and the Hyperion lab, which uses advanced single-cell spatial proteomics to better understand the tumor microenvironment. Together, these technologies allow Dr. Vinci’s team to investigate how these aggressive tumors develop and respond to potential treatments. This episode provides a rare behind-the-scenes look at how leading scientists and clinicians in Rome are pushing the boundaries of pediatric neuro-oncology and working to bring new hope to families facing devastating diagnoses. This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.
    続きを読む 一部表示
    23 分
まだレビューはありません